GLPG
Galapagos NV
Company Overview
| Mkt Cap | $2.00B | Price | $30.66 |
| Volume | 87.86K | Change | +1.39% |
| P/E Ratio | 27.1 | Open | $30.19 |
| Revenue | $275.6M | Prev Close | $30.24 |
| Net Income | $74.1M | 52W Range | $22.36 - $37.78 |
| Div Yield | N/A | Target | $32.50 |
| Overall | 35 | Value | 60 |
| Quality | -- | Technical | 10 |
No chart data available
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Latest News
Galapagos (0JXZ) Receives a Sell from Bank of America Securities
Galapagos (0JXZ) Gets a Sell from Kepler Capital
Galapagos NV Strengthens Board with Strategic Appointments
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLPG | $30.66 | +1.4% | 87.86K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |